293 related articles for article (PubMed ID: 28090687)
1. Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability. A total population study.
Bowring DL; Totsika V; Hastings RP; Toogood S; McMahon M
J Intellect Disabil Res; 2017 Jun; 61(6):604-617. PubMed ID: 28090687
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour.
Deb S; Unwin G; Deb T
J Intellect Disabil Res; 2015 Jan; 59(1):11-25. PubMed ID: 24450426
[TBL] [Abstract][Full Text] [Related]
3. Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study.
Sheehan R; Hassiotis A; Walters K; Osborn D; Strydom A; Horsfall L
BMJ; 2015 Sep; 351():h4326. PubMed ID: 26330451
[TBL] [Abstract][Full Text] [Related]
4. Psychotropic medication use in adolescents with intellectual disability living in the community.
Doan T; Ware R; McPherson L; van Dooren K; Bain C; Carrington S; Einfeld S; Tonge B; Lennox N
Pharmacoepidemiol Drug Saf; 2014 Jan; 23(1):69-76. PubMed ID: 23929635
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, patterns and factors associated with psychotropic use in older adults with intellectual disabilities in Ireland.
O'Dwyer M; Peklar J; Mulryan N; McCallion P; McCarron M; Henman MC
J Intellect Disabil Res; 2017 Oct; 61(10):969-983. PubMed ID: 28639298
[TBL] [Abstract][Full Text] [Related]
6. Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs.
Scheifes A; Walraven S; Stolker JJ; Nijman HL; Egberts TC; Heerdink ER
Res Dev Disabil; 2016; 49-50():13-21. PubMed ID: 26647003
[TBL] [Abstract][Full Text] [Related]
7. Problem behaviours and psychotropic medication use in intellectual disability: a multinational cross-sectional survey.
Perry BI; Cooray SE; Mendis J; Purandare K; Wijeratne A; Manjubhashini S; Dasari M; Esan F; Gunaratna I; Naseem RA; Hoare S; Chester V; Roy A; Devapriam J; Alexander R; Kwok HF
J Intellect Disabil Res; 2018 Feb; 62(2):140-149. PubMed ID: 29349928
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and patterns of anti-epileptic medication prescribing in the treatment of epilepsy in older adults with intellectual disabilities.
O'Dwyer M; Peklar J; Mulryan N; McCallion P; McCarron M; Henman MC
J Intellect Disabil Res; 2018 Mar; 62(3):245-261. PubMed ID: 29314463
[TBL] [Abstract][Full Text] [Related]
9. Proxy and self-reported Quality of Life in adults with intellectual disabilities: Impact of psychiatric symptoms, problem behaviour, psychotropic medication and unmet needs.
Koch AD; Vogel A; Becker T; Salize HJ; Voss E; Werner A; Arnold K; Schützwohl M
Res Dev Disabil; 2015; 45-46():136-46. PubMed ID: 26233765
[TBL] [Abstract][Full Text] [Related]
10. Psychotropic prescribing for persons with intellectual disabilities and other psychiatric disorders.
Edelsohn GA; Schuster JM; Castelnovo K; Terhorst L; Parthasarathy M
Psychiatr Serv; 2014 Feb; 65(2):201-7. PubMed ID: 24233105
[TBL] [Abstract][Full Text] [Related]
11. Psychotropic medication and psychotherapeutic treatment of adults with intellectual disabilities (PROMPT-ID): a cross-sectional, epidemiological study in Saxony, Germany.
Koch A; Dobrindt J; Schützwohl M
BMJ Open; 2018 Dec; 8(12):e025947. PubMed ID: 30573492
[TBL] [Abstract][Full Text] [Related]
12. Medication use among Australian adults with intellectual disability in primary healthcare settings: a cross-sectional study.
Doan TN; Lennox NG; Taylor-Gomez M; Ware RS
J Intellect Dev Disabil; 2013 Jun; 38(2):177-81. PubMed ID: 23550741
[TBL] [Abstract][Full Text] [Related]
13. Psychotropic drug use among people with intellectual disability before and after deinstitutionalization.
Nøttestad JA; Linaker OM
J Intellect Disabil Res; 2003 Sep; 47(Pt 6):464-71. PubMed ID: 12919197
[TBL] [Abstract][Full Text] [Related]
14. Mental disorder in adults with intellectual disability. 2: The rate of behaviour disorders among a community-based population aged between 16 and 64 years.
Deb S; Thomas M; Bright C
J Intellect Disabil Res; 2001 Dec; 45(Pt 6):506-14. PubMed ID: 11737537
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and characteristics of psychotropic drug use in institutionalized children and adolescents with mild intellectual disability.
Scheifes A; de Jong D; Stolker JJ; Nijman HL; Egberts TC; Heerdink ER
Res Dev Disabil; 2013 Oct; 34(10):3159-67. PubMed ID: 23886758
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and patterns of antipsychotic use and their associations with mental health and problem behaviours among older adults with intellectual disabilities.
O'Dwyer C; McCallion P; Henman M; McCarron M; O'Leary E; Burke E; O'Connell J; O'Dwyer M
J Appl Res Intellect Disabil; 2019 Jul; 32(4):981-993. PubMed ID: 31038275
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and associated factors of problem behaviours among older adults with intellectual disabilities in Ireland.
O'Dwyer C; McCallion P; Burke É; Carroll R; O'Dwyer M; McCarron M
Res Dev Disabil; 2018 Sep; 80():192-204. PubMed ID: 29880319
[TBL] [Abstract][Full Text] [Related]
18. Structured Medication Review to Improve Pharmacotherapy in People with Intellectual Disability and Behavioural Problems.
Scheifes A; Egberts TC; Stolker JJ; Nijman HL; Heerdink ER
J Appl Res Intellect Disabil; 2016 Jul; 29(4):346-55. PubMed ID: 25882186
[TBL] [Abstract][Full Text] [Related]
19. [Determinants of psychotropic medication in adults with mild or moderate intellectual disabilities].
Schützwohl M; Voss E; Stiawa M; Salize HJ; Puschner B; Koch A
Nervenarzt; 2017 Nov; 88(11):1273-1280. PubMed ID: 27638741
[TBL] [Abstract][Full Text] [Related]
20. Central nervous system medication use in older adults with intellectual disability: Results from the successful ageing in intellectual disability study.
Chitty KM; Evans E; Torr JJ; Iacono T; Brodaty H; Sachdev P; Trollor JN
Aust N Z J Psychiatry; 2016 Apr; 50(4):352-62. PubMed ID: 26019276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
